Investor Presentaiton
Investor presentation
First three months of 2017
Slide 98
R&D pipeline: Haemophilia and growth disorders
Product/project
Туре
Indication
N9-GP (NN7999)1
GlycoPEGylated long-acting rFIX
Haemophilia B
N8-GP (NN7088)
GlycoPEGylated long-acting rFVIII
Haemophilia A
Concizumab (NN7415)²
Monoclonal anti-TFPI
Somapacitan (NN8640)³ Once-weekly human growth hormone
Sc N8-GP (NN7170)
Phase 1 trial
Haemophilia A, B and with inhibitors
Growth disorder
Haemophilia A
1 Positive opinion received by CHMP in April 2017 and submitted to the US Food and Drug Administration in May 2016
2 Phase 1b trial completed
3 Phase 3 completed in Adult Growth Hormone Deficiency (AGHD)
Sc: Subcutanious
changing
diabetes®
Status (phase)
1
2
3
Filed Appr.
novo nordiskView entire presentation